Introduction: Cutaneous melanoma is rare in childhood and published studies have mainly been retrospective single-institution series or small case series. Given the absence of clinical protocols dedicated to pediatric melanoma, the treatment approach is generally extrapolated from the ones applied to adults.
84.0%, respectively (median follow-up 41.8 months). Tumor site, tumor stage, and ulceration influenced survival rates. Patients treated by pediatric oncologists (n = 140) were more likely to have advanced disease than those treated by dermatologists (n = 79).
Discussion: This study would suggest that the clinical history of melanoma in children and adolescents might resemble that of adult counterpart. Cooperative efforts are needed to make new drugs more readily available to pediatric patients to increase the outcome of patient with advanced disease.
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INTRODUCTION
Cutaneous melanoma is one of the common malignant tumors in adults, with an annual incidence rate of around 20 per 100,000 population. 1 Its incidence is also reportedly increasing by 4.1% a year (especially in older males). 2 Melanoma is still a rare disease in childhood, however, and only 1-2% of all cases occur in minors. It is noteworthy that, according to the definition adopted by pediatric cooperative groups for rare childhood tumors in Europe-that is, an annual incidence of less than two cases per million population 3-5 -melanoma is rare in children (its incidence being around 0.7-0.8 per million a year in the first decade of life), but not in adolescents, that is, patients between 15 and 19 years (with more than 10 per million in the second decade). [6] [7] [8] [9] Melanoma may actually qualify as an "orphan" disease in the world of pediatric oncology: published series have mainly been retrospective single-institution series and the few prospective studies conducted to date included a very small number of cases [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] ; scanty biological information is available on pediatric melanoma 30 ; there are no clinical protocols dedicated to pediatric melanoma patients, so their treatment is generally extrapolated from the approach applied to adults.
The present study was coordinated by the European Cooperative Study Group for Pediatric Rare Tumours (EXPeRT) 31, 32 in an effort to add to our knowledge on pediatric melanoma by pooling the findings of different national groups regarding the clinical characteristics, treatment modalities, and outcomes of children and adolescents with cutaneous melanoma.
PATIENTS AND METHODS
This study concerned patients prospectively registered under national Patients registered by the national groups had been treated at pediatric oncology wards, while those registered in the CMMR and in Israel had been treated at dermatology departments.
Inclusion criteria for this study were as follows: a histologically confirmed diagnosis of cutaneous melanoma, patient's age ≤18 years at diagnosis, a follow-up of > 3 months, and a diagnosis between 2002 and 2012. All patients, or their guardians, gave their informed consent to the collection of their data as established by the various registries and national regulation.
To obtain a uniform dataset for the analysis, the different national groups' prospectively collected clinical data were anonymized, validated by each national coordinator, and transferred to a standard EXPeRT data sheet. Clinical characteristics, family history, pathological features, treatment details, and follow-up data were recorded.
The histological diagnosis was provided by pathologists at the local centers and confirmed by national central pathology reviews based on the procedure adopted by each group. Clinical findings (e.g., Clark level, Breslow thickness, ulceration, nodal status) were also reviewed and, for the purpose of the present analysis, patients were reclassified according to the adult American Joint Committee on Cancer (AJCC) staging system (modified in 2009). 37 For each national project, the diagnostic and treatment guidelines reflected those adopted for adult melanoma. Sentinel lymph node biopsy (SLNB) was recommended in cases with a Breslow thickness > 0.75-1 mm, an increased mitotic rate, evidence of ulceration, and/or lymphovascular invasion; complete lymph node dissection was recommended in the event of a positive SLNB. In case of advanced disease, it was recommended to discuss the indication for systemic therapy with experts in the management of adult melanoma.
Statistical analysis
Data were pooled in a single master database at the Istituto Oncologico Veneto (Padova, Italy), where all statistical analyses were carried out. Continuous variables were summarized as median, interquartile range, and minimum and maximum. Categorical variables were reported as counts and percentages. Survival times were calculated from the date of diagnosis to that of the latest follow-up or event.
Disease-free survival (DFS) was set as the time elapsing between the date of the histological diagnosis and the date of first relapse, progression, or death. Overall survival (OS) was defined as the time from the date of the histological diagnosis to death due to any cause.
Patients still alive at the end of the study were censored at the date of their latest follow-up. The survival probability was computed using the Kaplan-Meier method, and heterogeneity in survival rates between different strata of selected variables was assessed using the log-rank test. The 3-year DFS and OS were reported along with their 95% confidence intervals (CIs). A P-value of < 0.05 was considered statistically significant. For univariate analysis, the DFS analysis was restricted to patients with disease status available. The characteristics of tumors and patients were compared between cases treated by dermatologists versus pediatricians using the chi-square or Fisher's exact test. All data analyses were conducted using the SAS statistical package (SAS, rel.
9.4; SAS Institute, Inc., Cary, NC).
RESULTS
The analysis included 219 patients with cutaneous melanoma, aged 0-18 years (median 14.4); 46.6% of them were adolescents and four were cases of congenital melanoma. Melanoma was reported in other family members of 10 patients. In 19.2% of cases, the melanoma developed on a nevus. Table 1 
Treatment
All patients underwent primary tumor resection. Initial surgery was reportedly complete in 106 cases. Second resection of the primary lesion was performed in 113 cases. SLNB was performed in 112 patients: it was reported to be done 
Overall survival and prognostic variables
The disease relapsed in 31 patients (14.2%), while information was missing on any events occurring in 24 cases (11%). The disease relapsed after a median of 13 months (range 6-30 months) and was local in one case, regional in four, metastatic in eight, and combined in six (and unspecified in 12).
At the time of our analysis, 195 patients were alive (188 without disease, three with disease, and five whose disease status was unknown), and 19 patients had died of their melanoma (five cases were lost to follow-up).
The OS and DFS at 3 years were 91.4% (95% CI: 85.8-94.9) and 84.0% (95% CI: 77.3-88.9), respectively, after a median follow-up of 41.8 months (range 18.7-59.5) for the patients still alive (Figs. 1 and 2 ).
At univariate analysis (Table 2) , the tumor's site of origin (P = 0.0020), ulceration status (P = 0.0024), T status (P = 0.0002), N 
TA B L E 2 Univariate analysis

Comparison of patients treated by dermatologists and patients treated by pediatric oncologists
The subset of cases registered under the national cooperative projects on pediatric rare tumors (n = 140) was compared with those collected from the German and Israeli dermatology registries (n = 79). As shown in Table 3 , pediatric oncologists saw significantly more children under 15 years old than dermatologists. Patients treated by the former were more likely to have advanced disease, that is, the T4 cases were 30%
and 19% (P = 0.0926), the N1 cases 31% and 12% (P = 0.0029), and the M1 cases 5% and 1% (P = 0.2646). The 3-year DFS was 77.6% and 93.7% (P = 0.0071) for the cases seen by the pediatric oncologists and those seen by the dermatologists, whereas OS was 87.1% and 98.7%
(P = 0.0061), respectively.
DISCUSSION
This observational analysis contains a relatively large number of pediatric melanoma cases prospectively registered and treated within a short period of time in several different countries. retrospective reports on other specific histotypes, [38] [39] [40] [41] [42] with the collection of cases deriving from prospective series seen in recent years by national cooperative groups taking part in the project.
This study included not only patients registered by the national cooperative pediatric oncology rare tumors groups (from Italy, Poland, Germany and France), and thus treated at pediatric oncology departments, but also patients registered within two dermatology registries (CMMR and Israel). This was by no means a pointless exercise because it has been reported that pediatric patients with melanoma are rarely seen at pediatric oncology centers (according to an Italian study, this applies to one in three children, and only one in 10 adolescents). 10 The comparison that we were thus able to perform showed that the cohorts of patients treated by pediatric oncologists and by dermatologists differed substantially: pediatric oncologists saw younger patients with more advanced disease. This would suggest that the more complicated cases are more likely to be referred to specialized oncology centers. This might mean that the higher likelihood of children having thicker lesions or N1 tumors by comparison with adults, as often claimed in the pediatric oncology literature, 10, 16, 17, 19, 24, 25 may relate more to a bias of referral than to an intrinsically greater aggressiveness of melanoma in pediatric age. In our series, for instance, the N1
cases accounted for 31% of the "pediatric oncology cohort", 12% of the "dermatology cohort", and 24% of the overall series; similarly, M1 cases accounted for 7%, 1%, and 4.5%, respectively. In spite of the limits of the series (e.g., it remains a hospital-based series, with case selection, not comparable to epidemiological series), the N1 and M1 proportions of our combined series are more close to the picture generally reported in adults, 43 for example, 9% of regional spread and 4% of distant spread In pediatric patients (as in adults), survival remains unsatisfactory for cases with advanced disease. In the absence of specific guidelines on the treatment for children and adolescents, their management has to be defaulted to the approach used for adults, though it is yet unclear whether melanoma developing at a very young age has the same biology (and the same tumor driving mutations) of adult melanoma. In our series, systemic therapy was given to 52% of AJCC stage III and to all AJCC IV patients. The heterogeneity of the series, the retrospective nature of the analysis (though patients were prospectively registered), and the lack of details on the administered therapy hindered the possibility to achieve conclusions on the efficacy of adjuvant therapy. However, survival rates did not differ between AJCC III treated with adjuvant therapy and those treated without it.
A specific major challenge regards the development of new agents. Recent discoveries (e.g., a better understanding of the genetic drivers 44, 45 and the mechanisms of immune regulation 46 Histologically, the differential diagnosis vis-à-vis melanocytic lesions of uncertain malignant potential also remains difficult in terms of the lesion's classification and interpretation (particularly in the young because of the higher likelihood of lesions with a spitzoid morphology in this age group). 57 The EXPeRT is developing a specific website for the nonscientific community (www.raretumors-children.eu), a virtual tumor board and advisory desk for professionals (vrt.cineca.it), harmonized and internationally recognized guidelines for most of the very rare pediatric tumors, and, ultimately, plans to create a joint international prospective case registry. Finally, the EXPeRT and the pediatric oncology reference centers should seek new partnerships, with adult medical oncology organizations, pharmaceutical companies, and regulatory authorities, for instance, to work toward the goal of offering new drugs to pediatric melanoma patients.
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